IP Library › Granted Patent US 12,668,645
Granted Patent B2
US 12,668,645 · App. 17/936,047 · Granted Jun 30, 2026

Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof

Inventors: Ronnie Rong Wei (Weston, MA); Ling Xu (Newton Center, MA); Zhi-Yong Yang (Newton Center, MA); Edward Seung (Medford, MA); Gary J. Nabel (Delray Beach, FL)
Assignee: ModeX Therapeutics, Inc.
C07K16/468A61P31/12A61P35/00C07K16/082C07K16/087C07K16/1009C07K16/1018C07K16/1027C07K16/1063C07K16/1081C07K16/125C07K16/1253C07K16/1275C07K16/1285C07K16/2803C07K16/2809C07K16/2818C07K16/2866C07K16/2878C07K16/2887C07K16/3076C07K19/00C07K2317/21C07K2317/24C07K2317/31C07K2317/73C07K2317/92C07K2319/41C07K2319/42C07K2319/43
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,668,645
App. No.
17/936,047
Filed
Sep 28, 2022
Granted
Jun 30, 2026
Kind
B2
Art Unit
1642
USPC
424/136.1
Abstract

Disclosed are antigen binding polypeptides and antigen binding polypeptide complexes (e.g., antibodies and antigen binding fragments thereof) having certain structural features. Also disclosed are polynucleotides and vectors encoding such polypeptides and polypeptide complexes; host cells; chimeric antigen receptors (CARs); immune cells; pharmaceutical compositions and kits containing such polypeptides and polypeptide complexes; and methods of using such polypeptides and polypeptide complexes.

Claims (29)

1 . A polypeptide having at least 95% identity to any one of SEQ ID NOs: 30 and 32-43; wherein the polypeptide comprises the sequences of:

(i) a heavy chain complementarity determining region (CDR) 1 comprising the sequence of SEQ ID NO: 64; a heavy chain CDR2 comprising the sequence of SEQ ID NO: 65; a heavy chain CDR3 comprising the sequence of SEQ ID NO: 66; a light chain CDR1 comprising the sequence of SEQ ID NO: 67; a light chain CDR2 comprising the sequence of SEQ ID NO: 68; and a light chain CDR3 comprising the sequence of SEQ ID NO: 69;

(ii) a heavy chain CDR1 comprising the sequence of SEQ ID NO: 82; a heavy chain CDR2 comprising the sequence of SEQ ID NO: 83; a heavy chain CDR3 comprising the sequence of SEQ ID NO: 84; a light chain CDR1 comprising the sequence of SEQ ID NO: 85; a light chain CDR2 comprising the sequence of SEQ ID NO: 86; and a light chain CDR3 comprising the sequence of SEQ ID NO: 87; and

(iii) a heavy chain CDR1 comprising the sequence of SEQ ID NO: 88; a heavy chain CDR2 comprising the sequence of SEQ ID NO: 89; a heavy chain CDR3 comprising the sequence of SEQ ID NO: 90; a light chain CDR1 comprising the sequence of SEQ ID NO: 91; a light chain CDR2 comprising the sequence of SEQ ID NO: 92; and a light chain CDR3 comprising the sequence of SEQ ID NO: 93.

2 . The polypeptide of claim 1 , having at least 97% identity to any one of SEQ ID NOs: 30 and 32-43.

3 . The polypeptide of claim 2 , having the sequence of any one of SEQ ID NOs: 30 and 32-43.

4 . The polypeptide of claim 1 , having at least 95% identity to the sequence of SEQ ID NO:30.

5 . The polypeptide of claim 1 , having at least 95% identity to the sequence of SEQ ID NO:32.

6 . The polypeptide of claim 1 , having at least 95% identity to the sequence of SEQ ID NO: 33.

7 . The polypeptide of claim 1 , having at least 95% identity to the sequence of SEQ ID NO: 34.

8 . The polypeptide of claim 1 , having at least 95% identity to the sequence of SEQ ID NO: 35.

9 . The polypeptide of claim 1 , having at least 95% identity to the sequence of SEQ ID NO: 36.

10 . The polypeptide of claim 1 , having at least 95% identity to the sequence of SEQ ID NO: 37.

11 . The polypeptide of claim 1 , having at least 95% identity to the sequence of SEQ ID NO: 38.

12 . The polypeptide of claim 1 , having at least 95% identity to the sequence of SEQ ID NO: 39.

13 . The polypeptide of claim 1 , having at least 95% identity to the sequence of SEQ ID NO: 40.

14 . The polypeptide of claim 1 , having at least 95% identity to the sequence of SEQ ID NO: 41.

15 . The polypeptide of claim 1 , having at least 95% identity to the sequence of SEQ ID NO: 42.

16 . The polypeptide of claim 1 , having at least 95% identity to the sequence of SEQ ID NO: 43.

17 . The polypeptide of claim 3 , having the sequence of SEQ ID NO: 30.

18 . The polypeptide of claim 3 , having the sequence of SEQ ID NO: 32.

19 . The polypeptide of claim 3 , having the sequence of SEQ ID NO: 33.

20 . The polypeptide of claim 3 , having the sequence of SEQ ID NO: 37.

21 . The polypeptide of claim 3 , having the sequence of SEQ ID NO: 38.

22 . The polypeptide of claim 3 , having the sequence of SEQ ID NO: 39.

23 . The polypeptide of claim 3 , having the sequence of SEQ ID NO: 40.

24 . The polypeptide of claim 3 , having the sequence of SEQ ID NO: 41.

25 . The polypeptide of claim 3 , having the sequence of SEQ ID NO: 42.

26 . The polypeptide of claim 3 , having the sequence of SEQ ID NO: 43.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2023
From: WEI, RONNIE RONG; XU, LING; YANG, ZHI-YONG; SEUNG, EDWARD; NABEL, GARY J.
To: MODEX THERAPEUTICS, INC.
Reel/Frame 063676/0163 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2023
From: WEI, RONNIE RONG; XU, LING; YANG, ZHI-YONG; SEUNG, EDWARD; NABEL, GARY J.
To: MODEX THERAPEUTICS
Reel/Frame 062268/0440 →
Continuity (7)
Provisional Application 63292382 · Dec 21, 2021
Provisional Application 63291305 · Dec 17, 2021
Provisional Application 63249833 · Sep 29, 2021
Provisional Application 63249919 · Sep 29, 2021
Provisional Application 63249722 · Sep 29, 2021
Provisional Application 63249794 · Sep 29, 2021
Related Publication 20230227553A1 · Jul 20, 2023
References Cited (104)
US 7129330B1 · Little et al. · 2006 [cited by applicant]
US 7951917B1 · Arathoon et al. · 2011 [cited by applicant]
US 8546543B2 · Lazar · 2013 [cited by applicant]
US 9221917B2 · Baurin · 2015 [cited by examiner]
US 9315578B2 · Kumagai et al. · 2016 [cited by applicant]
US 9315584B2 · Kumagai et al. · 2016 [cited by applicant]
US 9382329B2 · Chang et al. · 2016 [cited by applicant]
US 10118970B2 · Fuh et al. · 2018 [cited by applicant]
US 10131713B2 · Johnson et al. · 2018 [cited by applicant]
US 10633440B2 · Bonvini et al. · 2020 [cited by applicant]
US 10865248B2 · Lazar et al. · 2020 [cited by applicant]
US 10882922B2 · Yang et al. · 2021 [cited by applicant]
US 11046767B2 · Roobrouck et al. · 2021 [cited by applicant]
US 11149094B2 · Chiu et al. · 2021 [cited by applicant]
US 11180558B2 · Ross et al. · 2021 [cited by applicant]
US 11186649B2 · Wu et al. · 2021 [cited by applicant]
US 20050079170A1 · Le Gall et al. · 2005 [cited by applicant]
US 20090202532A1 · Kumagai et al. · 2009 [cited by applicant]
US 20100015133A1 · Igawa et al. · 2010 [cited by applicant]
US 20120095191A1 · Kumagai et al. · 2012 [cited by applicant]
US 20140322236A1 · Chambers et al. · 2014 [cited by applicant]
US 20150079088A1 · Lowman et al. · 2015 [cited by applicant]
US 20150225484A1 · Little et al. · 2015 [cited by applicant]
US 20160002357A1 · May et al. · 2016 [cited by applicant]
US 20160060330A1 · Presta · 2016 [cited by applicant]
US 20160194399A1 · Irving et al. · 2016 [cited by applicant]
US 20170129962A1 · Regula et al. · 2017 [cited by applicant]
US 20170247476A1 · Yan et al. · 2017 [cited by applicant]
US 20180155450A1 · Baurin et al. · 2018 [cited by applicant]
US 20180230225A1 · Fan et al. · 2018 [cited by applicant]
US 20180250322A1 · Devi et al. · 2018 [cited by applicant]
US 20190040155A1 · Ellwanger et al. · 2019 [cited by applicant]
US 20190169295A1 · Kufer et al. · 2019 [cited by applicant]
US 20200040075A1 · Michaels et al. · 2020 [cited by applicant]
US 20200071397A1 · Dipersio et al. · 2020 [cited by applicant]
US 20200071405A1 · Xiao et al. · 2020 [cited by applicant]
US 20200140552A1 · Wu et al. · 2020 [cited by applicant]
US 20200330587A1 · Kanekiyo et al. · 2020 [cited by applicant]
US 20200399369A1 · Asokan et al. · 2020 [cited by applicant]
US 20200405833A1 · Kluge et al. · 2020 [cited by applicant]
US 20210002376A1 · Seifert et al. · 2021 [cited by applicant]
US 20210061925A1 · Yang et al. · 2021 [cited by applicant]
US 20210137977A1 · Chaudhary · 2021 [cited by applicant]
US 20220041717A1 · Ross et al. · 2022 [cited by applicant]
US 20230203199A1 · Wei et al. · 2023 [cited by applicant]
US 20230235092A1 · Wei et al. · 2023 [cited by applicant]
US 20240034808A1 · Kamp et al. · 2024 [cited by applicant]
US 20240059798A1 · Xu et al. · 2024 [cited by applicant]
US 20240109955A1 · Li et al. · 2024 [cited by applicant]
EP 0979281B1 · 2005 [cited by applicant]
EP 1293514B1 · 2006 [cited by applicant]
EP 3156417A1 · 2017 [cited by applicant]
EP 2158221B1 · 2018 [cited by applicant]
EP 3049440B1 · 2020 [cited by applicant]
EP 3177646B1 · 2020 [cited by applicant]
EP 3164159B1 · 2020 [cited by applicant]
EP 3310811B1 · 2021 [cited by applicant]
EP 3365366B1 · 2021 [cited by applicant]
EP 3699194B1 · 2022 [cited by applicant]
WO WO9850431A2 · 1998 [cited by applicant]
WO WO2007108152A1 · 2007 [cited by applicant]
WO WO2008157379A2 · 2008 [cited by applicant]
WO WO2013138400A1 · 2013 [cited by applicant]
WO WO2015105926A1 · 2015 [cited by examiner]
WO WO2015173756A2 · 2015 [cited by applicant]
WO WO2017074878A1 · 2017 [cited by applicant]
WO WO2017180913A2 · 2017 [cited by applicant]
WO WO2018075564A1 · 2018 [cited by applicant]
WO WO2019195314A2 · 2019 [cited by applicant]
WO WO2019198051A2 · 2019 [cited by applicant]
WO WO2019231920A1 · 2019 [cited by applicant]
WO WO2020082045A1 · 2020 [cited by applicant]
WO WO2020088631A1 · 2020 [cited by applicant]
WO WO2020210386A1 · 2020 [cited by applicant]
WO WO2020210392A1 · 2020 [cited by applicant]
WO WO2020229553A1 · 2020 [cited by applicant]
WO WO2021058807A1 · 2021 [cited by applicant]
WO WO2021089748A2 · 2021 [cited by applicant]
WO WO2023056315A1 · 2023 [cited by applicant]
WO WO2024007013A2 · 2024 [cited by applicant]
Bendig, MM, “Humanization of Rodent Monoclonal Antibodies by CDR Grafting”, 1995, Methods: A Companion to Methods in Enzymology, 8, 83-93. (Year: 1995). [cited by examiner]
Rudikoff, S et. al. “Single amino acid substitution altering antigen-binding specificity”, 1982, Proceedings of the National Academy of Sciences USA, 79, 1979-1983. (Year: 1982). [cited by examiner]
Houdebine, LM, “Production of pharmaceutical proteins by transgenic animals”, 2009, Comparative Immunology, Microbiology, and Infectious Diseases, 32, 107-121. (Year: 2009). [cited by examiner]
Wall, RJ, “Transenic Livestock: Progress and Prospects for the Future”, 1996, Theriogenology, 45, 57-68. (Year: 1996). [cited by examiner]
Kappel, CA et. al. “Regulating gene expression in transgenic animals”, 1992, Current Opinion in Biotechnology, 3, 548-553. (Year: 1992). [cited by examiner]
Asano, R., et al., “Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics,” mAbs 6(5):1243-1254, Taylor… [cited by applicant]
Fellermeier, S., et al., “Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format,” Oncoimmunology 5(11):e1238540, Taylor & Francis, United States … [cited by applicant]
Onuoha, S. C., et al., “Rational design of antirheumatic prodrugs specific for sites of inflammation,” Arthritis & Rheumatology 67(10):2661-2672, Wiley, United States (Oct. 2015). [cited by applicant]
Pai, C. S., et al., “Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity,” The Journal of Clinical Investigation 129(1):349-363, American Society for Clinical Investigation, Uni… [cited by applicant]
Roskopf, C. C., et al., “T cell-recruiting triplebody 19-3-19 mediates serial lysis of malignant B-lymphoid cells by a single T cell,” Oncotarget 5(15):6466-6483, Impact Journals, United States (Aug. 2014). [cited by applicant]
Schubert, I., et al., “A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting,” mAbs 3(1):21-30, Taylor & Francis, United States (Jan.-Feb… [cited by applicant]
Schubert, I., et al., “A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen double-positive cells by dual-targeting,” mAbs 4(1):45-56, Taylor & Francis, United States (J… [cited by applicant]
Schubert, I., et al., “A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells,” mAbs 6(1):286-296, Taylor & Francis, United States (Jan.-Feb. 20… [cited by applicant]
Steinmetz, A., et al., “CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications,” mAbs 8(5):867-878, Taylor & Francis, United States (Jul. 2016). [cited by applicant]
Thiemann, M., et al., “A Single-Chain-Based Hexavalent CD27 Agonist Enhances T Cell Activation and Induces Anti-Tumor Immunity,” Frontiers in Oncology 8(387):1-17, Frontiers Research Foundation, Switzerland (Sep. 2018). [cited by applicant]
Co-pending U.S. Appl. No. 17/936,041, inventor Wei, R. R., et al., filed Sep. 28, 2022 (Not yet Published). [cited by applicant]
Co-pending U.S. Appl. No. 17/936,044, inventors Wei, R. R., et al.., filed Sep. 28, 2022 (Not yet Published). [cited by applicant]
Asokan, M., et al., “Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization,” J. Virol., 89(24):12501-12512, American Society for Microbiology, Washington, D.C. … [cited by applicant]
Fry, T.J., et al., “CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL,” Nat. Med., 24(1):20-28, Nature Portfolio, Berlin, Germany (Jan. 2018). [cited by applicant]
Padte, N.N., et al., “Engineering multi-specific antibodies against HIV-1,” Retrovirol., 15(1):60, BioMed Central, London, United Kingdom (Aug. 2018). [cited by applicant]
Steinhardt, J.J., et al., “Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity,” Nat. Commun., 9(877):1-12, Nature Portfolio, Berlin, Germany (Feb. 2018). [cited by applicant]
Xu, L., et al., “Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques,” Science, 358(6359)85-90, American Association for the Advancement of Science, Washington, D.C. (Oct. 2017). [cited by applicant]
Zhang, Y., et al., “Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma,” Front. Oncol., 11:664421, Frontiers Media SA, Lausanne, Switzerland (May 2021). [cited by applicant]
Third Party Observation for Int'l Application No. PCT/US2002/077202, Int'l Filing Date: Sep. 28, 2022, Date of Submission: Jan. 29, 2024, 19 pages. [cited by applicant]